Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
about
Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.Bacterial antibiotic resistance before and after clinical application in the United States.Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.Clinical efficacy of cefotaxime in serious infections.Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins.Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalisTentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazoneCefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.In vitro studies with cefotaxime: disk diffusion susceptibility testsGram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.Comparison of a beta-lactamase induction test with a test that detects low-frequency resistance to cefotaximeIn vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone.The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.
P2860
Q30451377-5A1083B4-EB1E-4C6A-985C-7CABC09CCEEAQ35119490-2B9011B4-0DB9-4E0D-AF9A-EAAB01DF3C08Q35668893-B5A56CBB-0BEB-4827-AC08-AC44C573C8DBQ35672598-B7325963-CE29-42EB-8C53-A838F848FE41Q35673235-8CB97DC5-C9D3-4999-8C36-308824C38A92Q35761805-AB74C1A6-0246-4101-9510-6B3F8357A262Q37258086-CF78E32D-418E-4A1A-9946-CFC3CAB59CFCQ37269692-8C80292E-1931-421B-AC9A-624DE284191AQ37291912-02E01777-5548-428F-8417-4885DA35449CQ37291928-FA698C05-7E74-4FD3-8E8B-8592911F7824Q37295928-5D69C0DE-ED5B-41F6-9022-A06A4447A003Q38591480-36D75FDA-34FD-402B-9EFE-03DE6A2023CEQ39849783-C86B5867-EFF3-4371-B651-E6CD444B4758Q39855480-2BE79799-35BD-4EC8-AD1D-6B7C5CAC77A0Q40584325-80F76DDC-FB43-491C-9924-907C9E7F8BC6
P2860
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
description
1980 nî lūn-bûn
@nan
1980 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@ast
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@en
type
label
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@ast
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@en
prefLabel
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@ast
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@en
P2093
P2860
P356
P1476
Cefotaxime: in vitro activity ...... r disk susceptibility testing.
@en
P2093
Gerlach EH
Sommers HM
Thornsberry C
P2860
P356
10.1128/AAC.18.1.88
P407
P577
1980-07-01T00:00:00Z